Loading
DOC1021 is a cancer vaccine from Diakonos Oncology Corporation, in registered phase 2 trials for glioma & glioblastoma, melanoma.
DOC1021 is listed on ClinicalTrials.gov as an intervention in 2 registered phase 2 trials sponsored by Diakonos Oncology Corporation, in glioma & glioblastoma, melanoma. A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A cancer vaccine, as described in the registry record: it trains the immune system against tumour antigens.
1.DOC1021 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"DOC1021" OR ABSTRACT:"DOC1021") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DOC1021, not a curated reading list.
Shares Melanoma and the tags pipeline, registry-only.
Shares Melanoma and the tags pipeline, registry-only.
Shares Melanoma and the tags pipeline, registry-only.
Shares Melanoma and the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.
Shares the tags pipeline, registry-only.